Track Axsome Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Axsome Therapeutics, Inc. AXSM · Stock Open Axsome Therapeutics, Inc. in new tab

141.69 USD
EPS
-3.03
P/B
70.67
ROE
-175.59
Beta
0.83
Target Price
265.86 USD
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Axsome Therapeutics reported robust Q3 2025 results, with total revenue rising 63% year-over-year to $171 million, driven by strong demand for AUVELITY and steady growth of SUNOSI.

  • AUVELITY sales reached $136.1 million, a 69% increase year-over-year, reflecting strong market traction.
  • SUNOSI revenues grew 35% year-over-year to $32.8 million, demonstrating ongoing commercial momentum.
  • Axsome submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation and plans to initiate multiple Phase III trials across ADHD and narcolepsy.
  • The company is well-positioned with a deep late-stage pipeline and a diverse portfolio of therapies addressing significant unmet needs in CNS health.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 22, 2027
EPS-3.03
Book Value2.01
Price to Book70.67
Debt/Equity212.67
% Insiders16.352%
Growth
Revenue Growth0.52%
Estimates
Forward P/E41.91
Forward EPS3.38
Target Mean Price265.86

DCF valuation

Model fair value for Axsome Therapeutics, Inc. (AXSM)
Result
Sign in to run the valuation for AXSM.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
21 analysts · consensus Strong buy · mean target 265.86 USD (low 220.00, high 315.00) · as of 15 Nov 2026
Low 220.00
Mean 265.86
High 315.00
Price 141.69
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Axsome Therapeutics, Inc. Logo Axsome Therapeutics, Inc. Analysis (AXSM)

United States Health Care Official Website Stock

Is Axsome Therapeutics, Inc. a good investment? Axsome Therapeutics, Inc. (AXSM) is currently trading at 141.69 USD. Market analysts have a consensus price target of 265.86 USD. This suggests a potential upside from current levels.

Earnings Schedule: Axsome Therapeutics, Inc. is expected to release its next earnings report on Feb. 22, 2027. The market consensus estimate for Forward EPS is 3.38.

Investor FAQ

Does Axsome Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Axsome Therapeutics, Inc.?

Axsome Therapeutics, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 22, 2027. The company currently has a trailing EPS of -3.03.

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Exchange Ticker
LSE (United Kingdom) 0HKF.L
FRA (Germany) 19X.F
STU (Germany) 19X.SG
NMS (United States) AXSM
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion